Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Hum Pathol. 2020 Sep;103:1-13. doi: 10.1016/j.humpath.2020.07.014. Epub 2020 Jul 15.
Renal neoplasia occurring as a second malignancy following childhood cancer has been most closely associated with neuroblastoma and Wilms tumor. While some cases have been associated with a genetic predisposition, nearly all are thought to result from "late effects" of therapy-related toxicity that involves chemotherapy or radiation. It is unclear if these tumors are enriched for specific molecular or morphologic characteristics. A query of our institutional nephrectomy registry of 8295 patients for renal neoplasia occurring post-treatment for childhood cancer revealed 6 patients with Wilms tumor, 4 with neuroblastoma, and 1 with acute lymphoblastic leukemia (ALL). Three additional cases of MiT family translocation renal cell carcinoma (RCC), from 2 patients, following chemotherapy for neuroblastoma and systemic lupus erythematosus and another of clear cell RCC post-ALL were included. The most common tumor type was clear cell RCC: 9/19 cases (47.4%), followed by metanephric adenoma and MiT family translocation RCC (3/19, 15.8%). There were no characteristic features to indicate a unique renal neoplasia subtype. Potential syndromic renal neoplasia occurred in 2 patients, metanephric adenomas and oncocytoma in a patient with hyperparathyroidism-jaw tumor syndrome post-treatment of Wilms tumor and a fumarate hydratase-deficient RCC in a patient post-treatment for ALL. The mean age at diagnosis of childhood neoplasia or treatment with chemotherapy or radiation was 4.7 years, and the average time to subsequent renal neoplasia was 31 years. Five (of 14) patients developed metastatic RCC, and there were 2 RCC-related deaths. These results indicate the need for extended clinical follow-up of these patients.
儿童癌症治疗后发生的肾肿瘤与神经母细胞瘤和肾母细胞瘤关系最为密切。虽然有些病例与遗传易感性有关,但几乎所有病例都被认为是与化疗或放疗相关的治疗毒性的“晚期效应”所致。目前尚不清楚这些肿瘤是否具有特定的分子或形态学特征。我们对机构肾切除术登记处的 8295 名接受过儿童癌症治疗的患者进行了检索,以寻找治疗后发生的肾肿瘤,结果发现 6 例肾母细胞瘤、4 例神经母细胞瘤和 1 例急性淋巴细胞白血病(ALL)。还包括 2 例神经母细胞瘤和系统性红斑狼疮化疗后和另 1 例 ALL 后发生的 MiT 家族易位肾细胞癌(RCC)的 3 例额外病例。最常见的肿瘤类型是透明细胞 RCC:19 例中有 9 例(47.4%),其次是中肾性腺瘤和 MiT 家族易位 RCC(3/19,15.8%)。没有特征性特征表明存在独特的肾肿瘤亚型。2 例患者发生了潜在的综合征性肾肿瘤,1 例为甲状旁腺腺瘤-颌骨肿瘤综合征患者在接受肾母细胞瘤治疗后发生的中肾性腺瘤和嗜酸细胞瘤,1 例为接受 ALL 治疗后发生的富马酸水合酶缺陷型 RCC。儿童期肿瘤诊断或接受化疗或放疗的平均年龄为 4.7 岁,随后发生肾肿瘤的平均时间为 31 年。5 例(14 例)患者发生转移性 RCC,有 2 例 RCC 相关死亡。这些结果表明需要对这些患者进行长期的临床随访。